Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
18 out of 18 results
-
Brooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles Risk
GSK’s THRIVE@50+ campaign with Brooke Shields encourages people aged 50 and over to discuss shingles risk and vaccination with their doctor.
Download (PDF, 207.8KB) -
GSK announces approval of Shingrix in China for prevention of shingles in adults aged 50 and over
National Medical Products Administration has approved Shingrix for the prevention of shingles (herpes zoster) in adults aged 50 or older.
-
Shingrix approved in the US for prevention of shingles in immunocompromised adults
Shingrix approved in the US for prevention of shingles in immunocompromised adults
-
New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+
This research was published in the Infectious Diseases Society of America’s Open Forum Infectious Diseases.
-
New long-term data show SHINGRIX continues to provide high protection against shingles in adults aged 50 and over for more than a decade
End-of-trial data show 79.7% efficacy in participants aged 50 years and over, six to 11 years after vaccination
Download (PDF, 192.8KB) -
GSK invests $100 million to expand long-term vaccine manufacturing capabilities in Hamilton, MT
New investment in its manufacturing site in Hamilton, MT to expand the production capacity of key components of the adjuvant system
-
GSK delivers sales and earnings growth in Q2 2019
Total EPS 19.5p, +>100% AER, +>100% CER; Adjusted EPS 30.5p +9% AER, +4% CER
-
GSK grants exclusive technology license for clinical-stage Ebola vaccines to Sabin Vaccine Institute
Transfer from GSK and partnership with NIAID will enable Sabin to advance development of the candidate vaccines
-
GSK receives prestigious Prix Galien USA award for SHINGRIX
SHINGRIX recognized as 2019 Best Pharmaceutical Product, following Galien Award win in Germany last week.
-
Low adult immunization rates decline further due to pandemic
Prior to pandemic, less than half of adults received the vaccines recommended for their age group.
-
GSK presents positive clinical data on maternal and older adults RSV candidate vaccines
Phase I/II data presented at ID Week show the two FDA fast-tracked candidate vaccines trigger robust immune response and are well-tolerated
-
Significant and Sustained Drop in Teen and Adult Immunization Rates During Pandemic, Study Shows
Significant and Sustained Drop in Teen and Adult Immunization Rates During Pandemic, Study Shows
-
New GSK to deliver step-change in growth and performance over next ten years driven by high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline
New GSK to positively impact health of >2.5 billion people next 10 years
-
US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes unanimously to recommend Shingrix for immunocompromised adults aged 19 and up
US CDC and Prevention’s Advisory Committee votes unanimously to recommend Shingrix for immunocompromised adults aged 19 & up
-
Routine Vaccination Rates in Teens and Adults Continue to Lag Behind Pre-Pandemic Levels, Follow-up Analysis Shows
The pandemic continues to negatively impact routine immunizations in the United States
-
GSK to present updates on its industry-leading infectious disease portfolio at IDWeek 2022
GSK will share updates on its industry-leading infectious disease pipeline and portfolio with 33 abstracts accepted for IDWeek 2022.
-
GSK launches national public awareness campaign to reverse steep decline in already low immunization rates for adults
GSK launches national public awareness campaign to reverse steep decline in already low immunization rates for adults
-
GSK announces positive topline data on co-administration of AREXVY and SHINGRIX
GSK announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the safety of AREXVY and SHINGRIX.
Download (PDF, 189.4KB)
